The Aptima HPV assay offers a unique screening approach by targeting high-risk human papillomavirus (HPV) mRNA from the E6/E7 oncogenes. The Aptima HPV assay offers the same excellent sensitivity and improved specificity as compared to DNA-based tests. Although up to 80% of the population will have an HPV infection at some point in life, very few will go on to develop cervical cancer. The Aptima HPV assay targets high-risk HPV mRNA. Studies have shown that mRNA reflects the presence and activity of a high-risk HPV infection. Identifying E6/E7 mRNA is indicative of those HPV infections destined to lead to disease.